Pharma’s Make-or-Break Moment: How AI Is Rewriting the Rules of Customer Engagement

Human relationships are and always will be the crux of meaningful customer engagements in the pharmaceutical industry. No channel rivals the impact of a well-prepared, well-supported representative. Our research shows that up to 70% of impactable sales are driven by field engagement – far more than direct to consumer (DTC) or non-personal promotion. Yet reps are navigating splintered customer relationship management (CRM) systems and incomplete data. Only 1 in 4 field teams feels fully supported by their CRM, showing that the base needs modernization. After years of patchwork tools, the field is asking for a seamless omnichannel experience that they can steer. 

We’re reaching a point where a rep can walk into a meeting with a single, AI-curated brief that merges medical insights, market trends and prior interactions. In-the-moment guidance can surface compliant content and suggest pivots based on real-time signals and post-call follow-up triggers digital sequences that actually land. AI can anticipate needs, recommend next best actions and connect what happens in a call to what happens across digital channels. It can make every interaction sharper, timelier and more relevant. 

But AI alone won’t deliver the reinvention the industry needs. The real shift is organizational: redesigning roles, workflows and governance so that AI becomes connective tissue across teams rather than a bolt-on tool.

This orchestration matters because the stakes are high. Pharma companies face a once-in-a-decade opportunity to move past legacy CRM and fragmented engagement models and build something more intelligent, coordinated and insight-driven. Those who act first will lower cost to serve, boost rep productivity and deliver customer experiences that feel personal, not programmatic. Those who wait risk falling behind as competitors turn engagement into a true differentiator.

AI changing the way work gets done

The conversation about AI in pharma often focuses on tools and features. But the deeper story is about work itself. AI doesn’t just automate tasks; it reshapes roles, ways of working, decision rights and how talent is deployed. It augments people and removes low-value work, freeing time for higher-value interactions. That means leaders must treat this as an operating-model shift — skills, incentives, workflows — not a point solution rollout. Reinvention is organizational, not just technical.

Consider the ripple effects: medical affairs, marketing and field teams working from a shared data spine rather than siloed systems. Compliance guardrails embedded in AI workflows, reducing risk while speeding execution. Governance models that define how human judgment and machine intelligence intersect. These changes aren’t optional — they’re prerequisites for making AI work at scale.

What does this look like on the ground? It starts with sharper call preparation: customer context, intent signals and recommended talking points delivered in one view. During the interaction, AI can surface next best actions and compliant content in real time, helping reps pivot as conversations evolve. After the call, AI can trigger personalized digital sequences that extend the dialogue and keep the customer engaged. The result isn’t just more touches — it’s better journeys, where every interaction builds on the last.

This shift also changes how success is measured. Volume metrics — number of calls, number of emails — are giving way to utility metrics: Did the interaction deliver value for the customer? Did it advance the relationship? AI makes those questions measurable by connecting engagement data across channels and surfacing insights that matter.

The value of getting this right

Why does this matter now? Because the economics of engagement are under pressure. Cost to serve is rising, while customer expectations for relevance and speed are climbing. Reinventing engagement with AI isn’t just about efficiency, it’s about growth. Companies that get this right will unlock new value pools by improving how they engage, not just how much they engage. They’ll move from fragmented, reactive models to insight-driven systems that anticipate needs and orchestrate responses across the enterprise.

The payoff is tangible: lower cost to serve, higher rep productivity and more consistent, personalized experiences for customers. But the window is closing. The recent wave of platform shifts exposed how brittle legacy CRM backbones are. AI-powered CRM now sets the pace, and leaders who hesitate risk being left behind.

What leaders should do next

So where should leaders start? First, pick one rep-critical journey — say, pre-call planning — and automate it end-to-end with AI. Measure the time you give back to the field. Second, create a single “frontline brief” that merges medical, market and interaction data for each key account. Third, tighten feedback loops between field and marketing so digital sequences adjust to what actually happened in the call. And finally, stand up lightweight governance for AI usage — content controls, compliance guardrails, human-in-the-loop oversight. These moves aren’t glamorous, but they build momentum and credibility for the broader transformation.

The bottom line

Reinventing customer engagement isn’t about swapping systems, it’s about designing work so every interaction creates value for the customer. AI can make that possible, but only if leaders treat it as an enterprise-wide transformation, not a tech project. The companies that get this right will redefine what good looks like in pharma — and set a new standard for the industry.

Photo: Thai Noipho, Getty Images

This post appears through the MedCity Influencers program. Anyone can publish their perspective on business and innovation in healthcare on MedCity News through MedCity Influencers. Click here to find out how.